The presence of fetal squamous cells in the maternal blood vessels of a woman who died during or after labor suggests that she had amniotic fluid embolism instead of pulmonary thromboembolism.

The patient displayed symptoms of pulmonary embolism shortly after giving birth, including acute shortness of breath, tachycardia, and tachypnea, as well as a wedge-shaped infarction on her chest x-ray. The resulting hypoventilation caused hypoxia. Given that pregnancy is a hypercoagulable state, there is an increased risk of thrombus formation and subsequent embolization, making pulmonary thromboembolism the primary differential diagnosis.

However, the histological findings during autopsy confirmed that the woman had amniotic fluid embolism, as fetal squamous cells were found in her maternal blood vessels. The risk of fetal and maternal blood mixing is highest during the third trimester and delivery, and fetal cells can act as thrombogenic factors. Although rare, this condition has a high mortality rate, and even those who survive often experience severe deficits, including neurological damage.

Fat embolism typically occurs after long bone fractures or orthopedic surgeries, while air embolism is very rare but can cause immediate death. Cholesterol embolization is a common scenario after cannulation, such as angiography, where the catheter mechanically displaces the cholesterol thrombus, leading to emboli.

Amniotic Fluid Embolism: A Rare but Life-Threatening Complication of Pregnancy

Amniotic fluid embolism is a rare but potentially fatal complication of pregnancy that occurs when fetal cells or amniotic fluid enter the mother’s bloodstream, triggering a severe reaction. Although many risk factors have been associated with this condition, such as maternal age and induction of labor, the exact cause remains unknown. It is believed that exposure of maternal circulation to fetal cells or amniotic fluid is necessary for the development of an amniotic fluid embolism, but the underlying pathology is not well understood.

The majority of cases occur during labor, but they can also occur during cesarean section or in the immediate postpartum period. Symptoms of amniotic fluid embolism include chills, shivering, sweating, anxiety, and coughing, while signs include cyanosis, hypotension, bronchospasms, tachycardia, arrhythmia, and myocardial infarction. However, there are no definitive diagnostic tests for this condition, and diagnosis is usually made by excluding other possible causes of the patient’s symptoms.

Management of amniotic fluid embolism requires immediate critical care by a multidisciplinary team, as the condition can be life-threatening. Treatment is primarily supportive, and the focus is on stabilizing the patient’s vital signs and providing respiratory and cardiovascular support as needed. Despite advances in medical care, the mortality rate associated with amniotic fluid embolism remains high, underscoring the need for continued research into the underlying causes and potential treatments for this rare but serious complication of pregnancy.

If a woman experiences postmenopausal bleeding, it is important for medical professionals to consider the possibility of endometrial cancer. According to NICE guidelines from 2015, women aged 55 or older with postmenopausal bleeding should be urgently referred for further evaluation.

One common method of evaluation is a transvaginal ultrasound, which can measure the thickness of the endometrial lining. A 3-mm cut-off is often used and has been found to be highly effective in detecting endometrial cancer. This method can also identify women who are unlikely to have endometrial cancer, which can help avoid more invasive procedures such as endometrial biopsy. However, some medical centers may use a cut-off of 4 mm or even 5 mm for endometrial biopsy.

In the case of a woman with an endometrial thickness of 6mm, the next step would be to perform an endometrial biopsy.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Symptoms of endometrial cancer include postmenopausal bleeding, which is usually slight and intermittent at first before becoming heavier, and changes in intermenstrual bleeding for premenopausal women. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness of less than 4 mm. Hysteroscopy with endometrial biopsy is also commonly used for diagnosis. Treatment for localized disease typically involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may require postoperative radiotherapy. Progestogen therapy may be used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

To test for ovulation in women with regular cycles, Day 21 progesterone (mid-luteal cycle progesterone) is used. However, for those with irregular cycles, progesterone should be tested a week before the predicted menstruation. Ovulation is necessary for fertilization to occur, as it indicates the release of an egg.

Oestrogen and Progesterone: Their Sources and Functions

Oestrogen and progesterone are two important hormones in the female body. Oestrogen is primarily produced by the ovaries, but can also be produced by the placenta and blood via aromatase. Its functions include promoting the development of genitalia, causing the LH surge, and increasing hepatic synthesis of transport proteins. It also upregulates oestrogen, progesterone, and LH receptors, and is responsible for female fat distribution. On the other hand, progesterone is produced by the corpus luteum, placenta, and adrenal cortex. Its main function is to maintain the endometrium and pregnancy, as well as to thicken cervical mucous and decrease myometrial excitability. It also increases body temperature and is responsible for spiral artery development.

It is important to note that these hormones work together in regulating the menstrual cycle and preparing the body for pregnancy. Oestrogen promotes the proliferation of the endometrium, while progesterone maintains it. Without these hormones, the menstrual cycle and pregnancy would not be possible. Understanding the sources and functions of oestrogen and progesterone is crucial in diagnosing and treating hormonal imbalances and reproductive disorders.

The ampulla of the fallopian tube is where fertilisation typically takes place.

Following its release from the ovary, the egg travels through the fimbria and into the ampulla. Once ovulation has occurred, the egg can only survive for approximately 24 hours.

Fertilisation predominantly occurs in the ampulla of the fallopian tube. After fertilisation, the resulting embryo remains in the fallopian tube for roughly 72 hours before reaching the end of the tube and being ready for implantation in the uterus.

If implantation happens outside of the uterus, it is referred to as an ectopic pregnancy.

Anatomy of the Uterus

The uterus is a female reproductive organ that is located within the pelvis and is covered by the peritoneum. It is supplied with blood by the uterine artery, which runs alongside the uterus and anastomoses with the ovarian artery. The uterus is supported by various ligaments, including the central perineal tendon, lateral cervical, round, and uterosacral ligaments. The ureter is located close to the uterus, and injuries to the ureter can occur when there is pathology in the area.

The uterus is typically anteverted and anteflexed in most women. Its topography can be visualized through imaging techniques such as ultrasound or MRI. Understanding the anatomy of the uterus is important for diagnosing and treating various gynecological conditions.

The most likely cause of the patient’s intractable vomiting during pregnancy is multiple gestation. This condition, known as hyperemesis gravidarum, is characterized by vomiting, dehydration, weight loss, and ketonuria. Multiple gestations can lead to hormone imbalances due to increased levels of βhCG, which can increase vomiting. Risk factors for multiple gestations include the use of fertility-enhancing treatments like IVF and older maternal age. The presence of the placental lambda sign is characteristic of a dichorionic pregnancy.

Complete molar pregnancy is an unlikely diagnosis as it typically presents with abnormal uterine bleeding, pelvic pain, and a snowstorm appearance on ultrasound. Partial molar pregnancy is also unlikely as it is associated with lower levels of βhCG and often has fetal parts present on ultrasound. Physiological vomiting, while common in pregnancy, is not the most likely cause in this case as the patient is experiencing weight loss and ketonuria.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, pre-term birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.

Women with migraine who use combined contraception have a higher risk of stroke. A transient ischemic attack (TIA) is a sign that a stroke may occur. The risk of stroke for women with migraine using combined contraception is 8 per 100,000 at age 20 and increases to 40 per 100,000 at age 40.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than one per 100 woman years. It is a convenient option that does not interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to consider. One of the main drawbacks is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections, so additional precautions may be necessary. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side effects such as headache, nausea, and breast tenderness may also be experienced.

Despite some reports of weight gain, a Cochrane review did not find a causal relationship between the combined oral contraceptive pill and weight gain. Overall, the combined oral contraceptive pill can be a safe and effective option for birth control, but it is important to weigh the pros and cons and discuss any concerns with a healthcare provider.

Gestational diabetes is the correct answer as it can result in foetal macrosomia, which is caused by insulin resistance promoting fat storage, and polyhydramnios, which is caused by foetal polyuria.

While maternal obesity may cause macrosomia, it does not necessarily lead to polyhydramnios.

Foetal gut atresia is a condition where part of the intestine is narrowed or absent, which can make it difficult for the foetus to ingest substances like amniotic fluid. This can result in excess amniotic fluid and polyhydramnios, but not macrosomia.

Hydrops fetalis may cause polyhydramnios, but it does not necessarily lead to macrosomia. However, it can cause hepatosplenomegaly.

Maternal hypercalcaemia may cause polyhydramnios, but it does not necessarily lead to macrosomia.

Gestational diabetes is a common medical disorder that affects around 4% of pregnancies. It can develop during pregnancy or be a pre-existing condition. According to NICE, 87.5% of cases are gestational diabetes, 7.5% are type 1 diabetes, and 5% are type 2 diabetes. Risk factors for gestational diabetes include a BMI of > 30 kg/m², previous gestational diabetes, a family history of diabetes, and family origin with a high prevalence of diabetes. Screening for gestational diabetes involves an oral glucose tolerance test (OGTT), which should be performed as soon as possible after booking and at 24-28 weeks if the first test is normal.

To diagnose gestational diabetes, NICE recommends using the following thresholds: fasting glucose is >= 5.6 mmol/L or 2-hour glucose is >= 7.8 mmol/L. Newly diagnosed women should be seen in a joint diabetes and antenatal clinic within a week and taught about self-monitoring of blood glucose. Advice about diet and exercise should be given, and if glucose targets are not met within 1-2 weeks of altering diet/exercise, metformin should be started. If glucose targets are still not met, insulin should be added to the treatment plan.

For women with pre-existing diabetes, weight loss is recommended for those with a BMI of > 27 kg/m^2. Oral hypoglycaemic agents, apart from metformin, should be stopped, and insulin should be commenced. Folic acid 5 mg/day should be taken from pre-conception to 12 weeks gestation, and a detailed anomaly scan at 20 weeks, including four-chamber view of the heart and outflow tracts, should be performed. Tight glycaemic control reduces complication rates, and retinopathy should be treated as it can worsen during pregnancy.

Targets for self-monitoring of pregnant women with diabetes include a fasting glucose level of 5.3 mmol/l and a 1-hour or 2-hour glucose level after meals of 7.8 mmol/l or 6.4 mmol/l, respectively. It is important to manage gestational diabetes and pre-existing diabetes during pregnancy to reduce the risk of complications for both the mother and baby.

Breast malignancy often leads to skin dimpling and nipple retraction, which are caused by the tumour infiltrating the breast ligaments and ducts. The axillary contents are enclosed by the clavipectoral fascia, and the breast’s lymphatic drainage occurs in both the axilla and internal mammary chain. The breast is highly vascularized, with the internal mammary artery being a subclavian artery branch.

The breast is situated on a layer of pectoral fascia and is surrounded by the pectoralis major, serratus anterior, and external oblique muscles. The nerve supply to the breast comes from branches of intercostal nerves from T4-T6, while the arterial supply comes from the internal mammary (thoracic) artery, external mammary artery (laterally), anterior intercostal arteries, and thoraco-acromial artery. The breast’s venous drainage is through a superficial venous plexus to subclavian, axillary, and intercostal veins. Lymphatic drainage occurs through the axillary nodes, internal mammary chain, and other lymphatic sites such as deep cervical and supraclavicular fossa (later in disease).

The preparation for lactation involves the hormones oestrogen, progesterone, and human placental lactogen. Oestrogen promotes duct development in high concentrations, while high levels of progesterone stimulate the formation of lobules. Human placental lactogen prepares the mammary glands for lactation. The two hormones involved in stimulating lactation are prolactin and oxytocin. Prolactin causes milk secretion, while oxytocin causes contraction of the myoepithelial cells surrounding the mammary alveoli to result in milk ejection from the breast. Suckling of the baby stimulates the mechanoreceptors in the nipple, resulting in the release of both prolactin and oxytocin from the pituitary gland (anterior and posterior parts respectively).

The likely cause of this patient’s amenorrhoea and galactorrhoea is a prolactinoma, which inhibits the secretion of GnRH and leads to low levels of oestrogen. Further tests, including a urinary pregnancy test and blood tests for various hormones, should be conducted to confirm the diagnosis. Asherman’s syndrome, intraductal papilloma, and pregnancy are less likely causes, as they do not present with the same symptoms or do not fit the patient’s reported history.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

The causes of amenorrhoea vary depending on the type. Primary amenorrhoea may be caused by gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, and thyrotoxicosis. Meanwhile, secondary amenorrhoea may be caused by stress, excessive exercise, PCOS, Sheehan’s syndrome, Asherman’s syndrome, and other underlying medical conditions.

To diagnose amenorrhoea, initial investigations may include pregnancy tests, full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels. Management of amenorrhoea involves treating the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause and treat the underlying cause accordingly. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis and other complications.

In conclusion, amenorrhoea is a condition that requires proper diagnosis and management. Understanding the causes and appropriate investigations can help in providing the necessary treatment and care for women experiencing this condition.

The peritoneum gives rise to the tunica vaginalis, which produces the fluid that occupies the hydrocele space.

Anatomy of the Scrotum and Testes

The scrotum is composed of skin and dartos fascia, with an arterial supply from the anterior and posterior scrotal arteries. It is also the site of lymphatic drainage to the inguinal lymph nodes. The testes are surrounded by the tunica vaginalis, a closed peritoneal sac, with the parietal layer adjacent to the internal spermatic fascia. The testicular arteries arise from the aorta, just below the renal arteries, and the pampiniform plexus drains into the testicular veins. The left testicular vein drains into the left renal vein, while the right testicular vein drains into the inferior vena cava. Lymphatic drainage occurs to the para-aortic nodes.

The spermatic cord is formed by the vas deferens and is covered by the internal spermatic fascia, cremasteric fascia, and external spermatic fascia. The cord contains the vas deferens, testicular artery, artery of vas deferens, cremasteric artery, pampiniform plexus, sympathetic nerve fibers, genital branch of the genitofemoral nerve, and lymphatic vessels. The vas deferens transmits sperm and accessory gland secretions, while the testicular artery supplies the testis and epididymis. The cremasteric artery arises from the inferior epigastric artery, and the pampiniform plexus is a venous plexus that drains into the right or left testicular vein. The sympathetic nerve fibers lie on the arteries, while the parasympathetic fibers lie on the vas. The genital branch of the genitofemoral nerve supplies the cremaster. Lymphatic vessels drain to lumbar and para-aortic nodes.

The combined oral contraceptive pill has been found to have a slightly higher risk of breast cancer, but it is protective against ovarian and endometrial cancer. Women with known breast cancer mutations like BRCA1 should avoid taking the pill as the risk may outweigh the benefits. Additionally, women with current breast cancer should not take the pill. After 5 years of use, there is a small increase in cervical cancer risk, which doubles after 10 years. However, cervical cancer is not a reason to avoid using the pill.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than one per 100 woman years. It is a convenient option that does not interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to consider. One of the main drawbacks is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections, so additional precautions may be necessary. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side effects such as headache, nausea, and breast tenderness may also be experienced.

Despite some reports of weight gain, a Cochrane review did not find a causal relationship between the combined oral contraceptive pill and weight gain. Overall, the combined oral contraceptive pill can be a safe and effective option for birth control, but it is important to weigh the pros and cons and discuss any concerns with a healthcare provider.

Pregnant women should discontinue the use of ACE inhibitors like ramipril or AIIRA like losartan as they have been linked to negative fetal outcomes. Labetalol is typically the preferred medication for managing hypertension during pregnancy, unless there are medical reasons not to use it.

Hypertension during pregnancy is a common condition that can be managed effectively with proper care. In normal pregnancy, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, if a pregnant woman develops hypertension, it is usually defined as a systolic blood pressure of over 140 mmHg or a diastolic blood pressure of over 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from booking readings can also indicate hypertension.

After confirming hypertension, the patient should be categorized into one of three groups: pre-existing hypertension, pregnancy-induced hypertension (PIH), or pre-eclampsia. PIH, also known as gestational hypertension, occurs in 3-5% of pregnancies and is more common in older women. If a pregnant woman takes an ACE inhibitor or angiotensin II receptor blocker for pre-existing hypertension, it should be stopped immediately, and alternative antihypertensives should be started while awaiting specialist review.

Pregnancy-induced hypertension in association with proteinuria, which occurs in around 5% of pregnancies, may also cause oedema. The 2010 NICE guidelines recommend oral labetalol as the first-line treatment for hypertension during pregnancy. Oral nifedipine and hydralazine may also be used, depending on the patient’s medical history. It is important to manage hypertension during pregnancy effectively to reduce the risk of complications and ensure the health of both the mother and the baby.

Effective contraception with the progestogen-only pill can be achieved immediately if it is started on the first to the fifth day of menstruation. However, if it is started at any other time or if the patient is uncertain, it is recommended to use additional contraceptive methods like condoms or abstinence for the first 48 hours.

Counselling for Women Considering the Progestogen-Only Pill

Women who are considering taking the progestogen-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. It is important to note that the POP should be taken at the same time every day, without a pill-free break, unlike the combined oral contraceptive (COC).

When starting the POP, immediate protection is provided if commenced up to and including day 5 of the cycle. If started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a COC, immediate protection is provided if continued directly from the end of a pill packet.

In case of missed pills, if the delay is less than 3 hours, the pill should be taken as usual. If the delay is more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours.

It is important to note that antibiotics have no effect on the POP, unless the antibiotic alters the P450 enzyme system. Liver enzyme inducers may reduce the effectiveness of the POP. In case of diarrhoea and vomiting, the POP should be continued, but it should be assumed that pills have been missed.

Finally, it is important to discuss sexually transmitted infections (STIs) with healthcare providers when considering the POP. By providing comprehensive counselling, women can make informed decisions about whether the POP is the right contraceptive choice for them.

Primary amenorrhoea is when a girl has not started menstruating by the age of 15, despite having normal secondary sexual characteristics, or by the age of 13 with no secondary sexual characteristics such as breast development or pubic hair growth. If a girl has not developed any secondary sexual characteristics by the age of 13, this could indicate primary amenorrhoea and should be investigated further with blood tests to rule out any hormonal issues such as Turner’s syndrome. However, if a girl is 8 years old and has not yet developed any secondary sexual characteristics, this is not a concern for primary amenorrhoea but may indicate precocious puberty, which requires treatment. On the other hand, if a 10-year-old girl has not yet developed any secondary sexual characteristics, this is a normal presentation and does not require investigation. Finally, if a 12-year-old girl has normal breast and pubic hair growth, she would need to have three more years of amenorrhoea before it is considered pathological.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

The causes of amenorrhoea vary depending on the type. Primary amenorrhoea may be caused by gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, and thyrotoxicosis. Meanwhile, secondary amenorrhoea may be caused by stress, excessive exercise, PCOS, Sheehan’s syndrome, Asherman’s syndrome, and other underlying medical conditions.

To diagnose amenorrhoea, initial investigations may include pregnancy tests, full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels. Management of amenorrhoea involves treating the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause and treat the underlying cause accordingly. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis and other complications.

In conclusion, amenorrhoea is a condition that requires proper diagnosis and management. Understanding the causes and appropriate investigations can help in providing the necessary treatment and care for women experiencing this condition.

Androgens play a crucial role in the development of male reproductive organs, as they stimulate the formation of Wolffian ducts that eventually give rise to the vas deferens, epididymis, and seminal vesicles. In the absence of androgen activity, the Wolffian ducts break down, leading to the failure of male reproductive organ development. Additionally, Sertoli cells produce anti-Mullerian hormone, which prevents the formation of female internal genitalia. The lack of androgen effects also results in the absence of masculine characteristics in the external genitalia.

Understanding Androgen Insensitivity Syndrome

Androgen insensitivity syndrome is a genetic condition that affects individuals with an XY genotype, causing them to develop a female phenotype due to their body’s resistance to testosterone. This condition was previously known as testicular feminization syndrome. Common features of this condition include primary amenorrhea, little to no pubic and axillary hair, undescended testes leading to groin swellings, and breast development due to the conversion of testosterone to estrogen.

Diagnosis of androgen insensitivity syndrome can be done through a buccal smear or chromosomal analysis, which reveals a 46XY genotype. After puberty, testosterone levels in individuals with this condition are typically in the high-normal to slightly elevated range for postpubertal boys.

Management of androgen insensitivity syndrome involves counseling and raising the child as female. Bilateral orchidectomy is recommended to reduce the risk of testicular cancer due to undescended testes. Additionally, estrogen therapy may be used to promote the development of secondary sexual characteristics. Understanding androgen insensitivity syndrome is crucial for proper diagnosis and management of affected individuals.

The woman’s history of molar pregnancy suggests choriocarcinoma as a potential complication. Bleeding lasting one month after vaginal trauma, vaginitis, or uterine atony is not normal. Endometrial cancer is unlikely in women of childbearing age.

Gestational trophoblastic disorders refer to a range of conditions that originate from the placental trophoblast. These disorders include complete hydatidiform mole, partial hydatidiform mole, and choriocarcinoma. Complete hydatidiform mole is a benign tumor of trophoblastic material that occurs when an empty egg is fertilized by a single sperm that duplicates its own DNA, resulting in all 46 chromosomes being of paternal origin. Symptoms of this disorder include bleeding in the first or early second trimester, exaggerated pregnancy symptoms, a large uterus for dates, and high levels of human chorionic gonadotropin (hCG) in the blood. Hypertension and hyperthyroidism may also be present. Urgent referral to a specialist center is necessary, and evacuation of the uterus is performed. Effective contraception is recommended to avoid pregnancy in the next 12 months. About 2-3% of cases may progress to choriocarcinoma. In partial mole, a normal haploid egg may be fertilized by two sperms or one sperm with duplication of paternal chromosomes, resulting in DNA that is both maternal and paternal in origin. Fetal parts may be visible, and the condition is usually triploid.

Bacterial Vaginosis and Other Causes of Vaginal Discharge

Vaginal discharge is a common concern among women, and bacterial vaginosis (BV) is the most common non-STI-related cause. BV occurs when there is an imbalance in the normal flora of the vaginal mucosa, which is mostly made up of Lactobacilli. These bacteria produce hydrogen peroxide, which helps to maintain a healthy pH level in the vagina by killing off anaerobes. However, disruptions to the normal flora, such as the use of new products or hormonal imbalances, can lead to the death of Lactobacilli and an increase in pH. This creates an environment where anaerobes like Gardnerella vaginalis can thrive and cause BV.

Candidiasis, caused by the fungus Candida albicans, is the second most common cause of non-STI-related vaginal discharge. It is characterized by thick white curds attached to the vaginal mucosa and is often associated with vulval itching. However, this patient does not describe these symptoms.

It is important to note that sexually transmitted infections like chlamydia, gonorrhoeae, and trichomoniasis can also cause vaginal discharge. However, there is no indication in this patient’s clinical history that she may be affected by any of these infections. the causes of vaginal discharge can help women identify when they need to seek medical attention and receive appropriate treatment.

A pregnant woman who has 3 risk factors should receive LMWH from 28 weeks until 6 weeks after giving birth. If she has more than 3 risk factors, she should start LMWH immediately and continue until 6 weeks postnatal.

The risk factors for thromboprophylaxis include age over 35, a body mass index over 30, parity over 3, smoking, gross varicose veins, current pre-eclampsia, immobility, family history of unprovoked VTE, low risk thrombophilia, multiple pregnancy, and IVF pregnancy.

In this particular case, the woman has 4 risk factors, including being 36 years old, a smoker, having a parity over 3, and a body mass index of 33. Therefore, she needs to begin taking low molecular weight heparin immediately and continue until 6 weeks after giving birth.

While all pregnant women should be advised to stay mobile and hydrated, this woman requires medical treatment due to her increased risk factors.

Pregnancy increases the risk of developing venous thromboembolism (VTE), which is why it is important to assess a woman’s individual risk during pregnancy and take appropriate prophylactic measures. A risk assessment should be conducted at the time of booking and on any subsequent hospital admission. Women with a previous VTE history are automatically considered high risk and require low molecular weight heparin throughout the antenatal period, along with input from experts. Women at intermediate risk due to hospitalization, surgery, comorbidities, or thrombophilia should also be considered for antenatal prophylactic low molecular weight heparin.

The risk assessment at booking should include factors that increase the likelihood of developing VTE, such as age over 35, body mass index over 30, parity over 3, smoking, gross varicose veins, current pre-eclampsia, immobility, family history of unprovoked VTE, low-risk thrombophilia, multiple pregnancy, and IVF pregnancy. If a woman has four or more risk factors, immediate treatment with low molecular weight heparin should be initiated and continued until six weeks postnatal. If a woman has three risk factors, low molecular weight heparin should be initiated from 28 weeks and continued until six weeks postnatal.

If a diagnosis of DVT is made shortly before delivery, anticoagulation treatment should be continued for at least three months, as in other patients with provoked DVTs. Low molecular weight heparin is the preferred treatment for VTE prophylaxis in pregnancy, while Direct Oral Anticoagulants (DOACs) and warfarin should be avoided. By taking these measures, the risk of developing VTE during pregnancy can be reduced.

When a cervical smear sample tests positive for high-risk HPV (hrHPV), it undergoes cytological examination to check for abnormal cellular changes that may indicate early cervical cancer. In the UK, cervical screening is offered to women between the ages of 25 and 65, with those aged 25-50 offered a smear every 3 years and those aged 50-65 offered a smear every 5 years. The aim of the screening programme is to detect cervical changes early on. HPV, a sexually transmitted virus, is present in almost all sexually active individuals, and HPV 16 or 18 is present in almost all cases of cervical cancer. If hrHPV is not detected, no further testing is required, and the patient can return to routine screening. Repeating the smear is not necessary following the presence of hrHPV, but a repeat smear may be required if the laboratory report an inadequate sample. Prior to colposcopy investigation, the sample must be positive for hrHPV and dyskaryosis.

Understanding Cervical Cancer Screening Results

The cervical cancer screening program has evolved significantly in recent years, with the introduction of HPV testing allowing for further risk stratification. The NHS now uses an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

If the hrHPV test is negative, individuals can return to normal recall, unless they fall under the test of cure pathway, untreated CIN1 pathway, or require follow-up for incompletely excised cervical glandular intraepithelial neoplasia (CGIN) / stratified mucin producing intraepithelial lesion (SMILE) or cervical cancer. If the hrHPV test is positive, samples are examined cytologically, and if the cytology is abnormal, individuals will require colposcopy.

If the cytology is normal but the hrHPV test is positive, the test is repeated at 12 months. If the repeat test is still hrHPV positive and cytology is normal, a further repeat test is done 12 months later. If the hrHPV test is negative at 24 months, individuals can return to normal recall, but if it is still positive, they will require colposcopy. If the sample is inadequate, it will need to be repeated within 3 months, and if two consecutive samples are inadequate, colposcopy will be required.

For individuals who have previously had CIN, they should be invited for a test of cure repeat cervical sample in the community 6 months after treatment. The most common treatment for cervical intraepithelial neoplasia is large loop excision of transformation zone (LLETZ), which may be done during the initial colposcopy visit or at a later date depending on the individual clinic. Cryotherapy is an alternative technique.

Fertilization happens when a sperm reaches an egg that has been released during ovulation. The process begins with the sperm penetrating the outer layer of the egg, called the corona radiata, using enzymes in the plasma membrane of its head. These enzymes bind to receptors on the next inner layer of the egg, called the zona pellucida, triggering the acrosome reaction. This reaction causes the acrosomal hydrolytic enzymes to digest the zona pellucida, creating a pathway to the egg’s plasma membrane. The sperm then enters the egg’s cytoplasm, and the two cells fuse together to form a diploid zygote. The sperm also stimulates the release of calcium ions from the cortical granules of the egg, which inactivate the receptors on the zona pellucida to prevent polyspermy. After fertilization, the zygote undergoes rapid mitotic cell divisions to form an embryo.

The Process of Fertilisation

Fertilisation is the process by which a sperm cell reaches and penetrates an egg cell that has been released during ovulation. The first step involves the sperm penetrating the corona radiata, which is the outer layer of the ovum, using enzymes in the plasma membrane of the sperm’s head. These enzymes bind to the ZP3 receptors on the zona pellucida, which is the next inner layer of the ovum, triggering the acrosome reaction. This reaction involves the acrosomal hydrolytic enzymes digesting the zona pellucida, creating a pathway to the ovum plasma membrane.

Once the sperm enters the ovum cytoplasm, the two cells fuse together, resulting in the formation of a diploid zygote. The sperm also stimulates the release of calcium ions from the cortical granules of the ovum, which inactivate the ZP3 receptors to prevent polyspermy. After fertilisation, rapid mitotic cell divisions occur, resulting in the production of an embryo.

In summary, fertilisation is a complex process that involves the penetration of the ovum by the sperm, the fusion of the two cells, and the subsequent development of the zygote into an embryo.

Anti-oestrogen drugs are used in the management of oestrogen receptor-positive breast cancer. Selective oEstrogen Receptor Modulators (SERM) such as Tamoxifen act as an oestrogen receptor antagonist and partial agonist. However, Tamoxifen may cause adverse effects such as menstrual disturbance, hot flushes, venous thromboembolism, and endometrial cancer. On the other hand, aromatase inhibitors like Anastrozole and Letrozole reduce peripheral oestrogen synthesis, which is important in postmenopausal women. Anastrozole is used for ER +ve breast cancer in this group. However, aromatase inhibitors may cause adverse effects such as osteoporosis, hot flushes, arthralgia, myalgia, and insomnia. NICE recommends a DEXA scan when initiating a patient on aromatase inhibitors for breast cancer.

Anatomy of the Scrotum and Testes

The scrotum is composed of skin and dartos fascia, with an arterial supply from the anterior and posterior scrotal arteries. It is also the site of lymphatic drainage to the inguinal lymph nodes. The testes are surrounded by the tunica vaginalis, a closed peritoneal sac, with the parietal layer adjacent to the internal spermatic fascia. The testicular arteries arise from the aorta, just below the renal arteries, and the pampiniform plexus drains into the testicular veins. The left testicular vein drains into the left renal vein, while the right testicular vein drains into the inferior vena cava. Lymphatic drainage occurs to the para-aortic nodes.

The spermatic cord is formed by the vas deferens and is covered by the internal spermatic fascia, cremasteric fascia, and external spermatic fascia. The cord contains the vas deferens, testicular artery, artery of vas deferens, cremasteric artery, pampiniform plexus, sympathetic nerve fibers, genital branch of the genitofemoral nerve, and lymphatic vessels. The vas deferens transmits sperm and accessory gland secretions, while the testicular artery supplies the testis and epididymis. The cremasteric artery arises from the inferior epigastric artery, and the pampiniform plexus is a venous plexus that drains into the right or left testicular vein. The sympathetic nerve fibers lie on the arteries, while the parasympathetic fibers lie on the vas. The genital branch of the genitofemoral nerve supplies the cremaster. Lymphatic vessels drain to lumbar and para-aortic nodes.

If a patient with primary amenorrhea has elevated FSH/LH levels, it may indicate the presence of gonadal dysgenesis.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

The causes of amenorrhoea vary depending on the type. Primary amenorrhoea may be caused by gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, and thyrotoxicosis. Meanwhile, secondary amenorrhoea may be caused by stress, excessive exercise, PCOS, Sheehan’s syndrome, Asherman’s syndrome, and other underlying medical conditions.

To diagnose amenorrhoea, initial investigations may include pregnancy tests, full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels. Management of amenorrhoea involves treating the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause and treat the underlying cause accordingly. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis and other complications.

In conclusion, amenorrhoea is a condition that requires proper diagnosis and management. Understanding the causes and appropriate investigations can help in providing the necessary treatment and care for women experiencing this condition.

The first step in screening for cervical cancer in women aged 25-64 is to test their cervical smear samples for high-risk HPV. If the test is positive, the same sample is then analyzed for abnormal cytology. The recommended frequency of smear tests is every 3 years for women aged 25-49 and every 5 years for women aged 50-64 in the UK screening programme. Therefore, the statements All women are initially screened for abnormal cytology between the ages of 18-64, All women are initially screened for abnormal cytology between the ages of 25-64, and All women are initially screened for abnormal cytology between the ages of 30-64 are incorrect as they either refer to the wrong screening test or age range.

Understanding Cervical Cancer Screening Results

The cervical cancer screening program has evolved significantly in recent years, with the introduction of HPV testing allowing for further risk stratification. The NHS now uses an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

If the hrHPV test is negative, individuals can return to normal recall, unless they fall under the test of cure pathway, untreated CIN1 pathway, or require follow-up for incompletely excised cervical glandular intraepithelial neoplasia (CGIN) / stratified mucin producing intraepithelial lesion (SMILE) or cervical cancer. If the hrHPV test is positive, samples are examined cytologically, and if the cytology is abnormal, individuals will require colposcopy.

If the cytology is normal but the hrHPV test is positive, the test is repeated at 12 months. If the repeat test is still hrHPV positive and cytology is normal, a further repeat test is done 12 months later. If the hrHPV test is negative at 24 months, individuals can return to normal recall, but if it is still positive, they will require colposcopy. If the sample is inadequate, it will need to be repeated within 3 months, and if two consecutive samples are inadequate, colposcopy will be required.

For individuals who have previously had CIN, they should be invited for a test of cure repeat cervical sample in the community 6 months after treatment. The most common treatment for cervical intraepithelial neoplasia is large loop excision of transformation zone (LLETZ), which may be done during the initial colposcopy visit or at a later date depending on the individual clinic. Cryotherapy is an alternative technique.

How does the Combined Oral Contraceptive Pill work?

The Combined Oral Contraceptive Pill (COC) is a widely used method of contraception in the UK. It works by preventing ovulation, which means that an egg is not released from the ovaries. In addition to this, the COC also thickens the cervical mucus, making it more difficult for sperm to enter the uterus, and thins the endometrial lining, reducing the chance of implantation.

By combining these three actions, the COC is highly effective at preventing pregnancy. It is important to note that the COC does not protect against sexually transmitted infections (STIs), so additional protection such as condoms should be used if there is a risk of STIs.

Pelvic inflammatory disease is most commonly caused by chlamydia and gonorrhoeae, with gonorrhoeae being the likely cause in this patient since they do not have chlamydia. While HIV does not directly cause pelvic inflammatory disease, it can increase the risk of contracting sexually transmitted infections. Syphilis follows its own distinct clinical course and does not cause pelvic inflammatory disease, while herpes typically presents with painful genital blisters but does not cause pelvic inflammatory disease.

Pelvic inflammatory disease (PID) is a condition where the female pelvic organs, including the uterus, fallopian tubes, ovaries, and surrounding peritoneum, become infected and inflamed. It is typically caused by an infection that spreads from the endocervix. The most common causative organism is Chlamydia trachomatis, followed by Neisseria gonorrhoeae, Mycoplasma genitalium, and Mycoplasma hominis. Symptoms of PID include lower abdominal pain, fever, dyspareunia, dysuria, menstrual irregularities, vaginal or cervical discharge, and cervical excitation.

To diagnose PID, a pregnancy test should be done to rule out an ectopic pregnancy, and a high vaginal swab should be taken to screen for Chlamydia and gonorrhoeae. However, these tests may often be negative, so consensus guidelines recommend having a low threshold for treatment due to the potential complications of untreated PID. Management typically involves oral ofloxacin and oral metronidazole or intramuscular ceftriaxone, oral doxycycline, and oral metronidazole. In mild cases of PID, intrauterine contraceptive devices may be left in, but the evidence is limited, and removal of the IUD may be associated with better short-term clinical outcomes according to recent guidelines.

Complications of PID include perihepatitis (Fitz-Hugh Curtis Syndrome), which occurs in around 10% of cases and is characterized by right upper quadrant pain that may be confused with cholecystitis, infertility (with a risk as high as 10-20% after a single episode), chronic pelvic pain, and ectopic pregnancy.

The patient’s symptom is non-specific and could have various causes. However, given her age and the fact that she has lost a friend to ovarian cancer, it is reasonable to perform a simple test to rule out this possibility and alleviate her concerns. It is important to note that the patient does not exhibit any other common symptoms associated with ovarian cancer, such as weight loss.

CA-125 is a tumour marker for ovarian cancer, while CA19-9 is associated with pancreatic cancer. CEA is a marker for bowel cancer, and colonoscopy may be considered if the patient presents with additional symptoms that suggest gastrointestinal disease.

Understanding Ovarian Cancer: Risk Factors, Symptoms, and Management

Ovarian cancer is a type of cancer that affects women, with the peak age of incidence being 60 years. It is the fifth most common malignancy in females and carries a poor prognosis due to late diagnosis. Around 90% of ovarian cancers are epithelial in origin, with 70-80% of cases being due to serous carcinomas. Interestingly, recent studies suggest that the distal end of the fallopian tube is often the site of origin of many ‘ovarian’ cancers.

There are several risk factors associated with ovarian cancer, including a family history of mutations of the BRCA1 or the BRCA2 gene, early menarche, late menopause, and nulliparity. Clinical features of ovarian cancer are notoriously vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms, early satiety, and diarrhea.

To diagnose ovarian cancer, a CA125 test is usually done initially. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 should not be used for screening for ovarian cancer in asymptomatic women. Diagnosis is difficult and usually involves diagnostic laparotomy.

Management of ovarian cancer usually involves a combination of surgery and platinum-based chemotherapy. The prognosis for ovarian cancer is poor, with 80% of women having advanced disease at presentation and the all stage 5-year survival being 46%. It is traditionally taught that infertility treatment increases the risk of ovarian cancer, as it increases the number of ovulations. However, recent evidence suggests that there is not a significant link. The combined oral contraceptive pill reduces the risk (fewer ovulations) as does having many pregnancies.

During pregnancy, the depth of breathing increases, which is known as tidal volume. This is caused by progesterone relaxing the intercostal muscles and diaphragm, allowing for greater lung inflation during breathing. This is a normal change and is not caused by oestrogen, which typically causes other physical changes during pregnancy such as spider naevi, palmar erythema, and skin pigmentation.

Other physiological changes that occur during pregnancy include increased uterine size, cervical ectropion, increased vaginal discharge, increased plasma volume, anaemia, increased white blood cell count, platelets, ESR, cholesterol, and fibrinogen, as well as decreased albumin, urea, and creatinine. Progesterone-related effects during pregnancy include decreased blood pressure, constipation, ureteral dilation, bladder relaxation, biliary stasis, and increased tidal volume.

During pregnancy, a woman’s body undergoes various physiological changes. The cardiovascular system experiences an increase in stroke volume, heart rate, and cardiac output, while systolic blood pressure remains unchanged and diastolic blood pressure decreases in the first and second trimesters before returning to normal levels by term. The enlarged uterus may cause issues with venous return, leading to ankle swelling, supine hypotension, and varicose veins.

The respiratory system sees an increase in pulmonary ventilation and tidal volume, with oxygen requirements only increasing by 20%. This can lead to a sense of dyspnea due to over-breathing and a fall in pCO2. The basal metabolic rate also increases, potentially due to increased thyroxine and adrenocortical hormones.

Maternal blood volume increases by 30%, with red blood cells increasing by 20% and plasma increasing by 50%, leading to a decrease in hemoglobin levels. Coagulant activity increases slightly, while fibrinolytic activity decreases. Platelet count falls, and white blood cell count and erythrocyte sedimentation rate rise.

The urinary system experiences an increase in blood flow and glomerular filtration rate, with elevated sex steroid levels leading to increased salt and water reabsorption and urinary protein losses. Trace glycosuria may also occur.

Calcium requirements increase during pregnancy, with gut absorption increasing substantially due to increased 1,25 dihydroxy vitamin D. Serum levels of calcium and phosphate may fall, but ionized calcium levels remain stable. The liver experiences an increase in alkaline phosphatase and a decrease in albumin levels.

The uterus undergoes significant changes, increasing in weight from 100g to 1100g and transitioning from hyperplasia to hypertrophy. Cervical ectropion and discharge may increase, and Braxton-Hicks contractions may occur in late pregnancy. Retroversion may lead to retention in the first trimester but usually self-corrects.

Hyperemesis gravidarum is a condition that causes severe nausea and vomiting during pregnancy, leading to weight loss. Abdominal pain is not a common symptom and may indicate another gastrointestinal disorder.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, pre-term birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.

Anaemia in pregnancy results from a greater increase in plasma volume compared to haemoglobin concentration, leading to a dilution of haemoglobin levels. It is important to note that haemoglobin levels actually increase during pregnancy. Drinking more water does not cause anaemia, as any excess water would be eliminated by the kidneys. Additionally, reduced secretion of ADH does not occur during pregnancy and would result in diuresis rather than anaemia.

During pregnancy, women are checked for anaemia twice – once at the initial booking visit (usually at 8-10 weeks) and again at 28 weeks. The National Institute for Health and Care Excellence (NICE) has set specific cut-off levels to determine if a woman requires oral iron therapy. For the first trimester, the cut-off is less than 110 g/L, for the second and third trimesters, it is less than 105 g/L, and for the postpartum period, it is less than 100 g/L. If a woman falls below these levels, she should receive oral ferrous sulfate or ferrous fumarate. Treatment should continue for three months after iron deficiency is corrected to allow for the replenishment of iron stores.